U.S. telehealth company Hims & Hers Health on Wednesday said it will sell compounded versions of Novo Nordisk's popular ...

Lawsuit is part of a nationwide strategy by Novo Nordisk to protect its trademark and profits from its blockbuster GLP-1 ...

Medicare may cover Wegovy for adults with cardiovascular disease and either obesity or overweight. Learn more about Medicare ...

Novo Nordisk has multiple, strong upcoming, positive catalysts, related to its GLP-1 weight-loss drugs, Ozempic and Wegovy.

Many people are doing an end-run around their doctor's office, reaching out to potentially unreliable sources that promise to ...

Wegovy, Zepbound and other cutting-edge weight-loss drugs can be tough to get these days. They’re in short supply, and often ...

We need to take stock of the promises and limitations of new “miracle” weight loss drugs and treat the cause of weight gain, ...

Certain blockbuster weight-loss drugs have been found to protect the heart in significant ways, and new research suggests ...

This summary of recent health news includes U.S. Senator Bernie Sanders advocating for cheaper Ozempic, new findings on ...

Novo Nordisk CEO Lars Jorgensen is set to testify before the Senate Committee on Health, Education, Labor and Pensions (HELP) ...

There is soaring demand for weight-loss drugs in the GLP-1 class, and the company will now sell it to certain professions for ...

Obesity-focused biotech BioAge Labs said on Wednesday it was seeking a valuation of as much as $587 million in its initial public offering in the United States, according to a regulatory filing.